Reader-Supported · Editorially Reviewed
Evidence Watch · Peer-reviewed heart failure trial

9.8% Average Loss With Semaglutide in HFpEF and Type 2 Diabetes

STEP-HFpEF DM studied once-weekly semaglutide in adults who had obesity-related heart failure with preserved ejection fraction and type 2 diabetes. It found improvements in weight and a patient-reported heart-failure health-status score under a one-year trial protocol. The study is not a substitute for heart-failure or diabetes care and does not establish an HFpEF indication.

Last reviewed September 2026
1 study cited
New England Journal of MedicineMulticountry, double-blind, randomized, placebo-controlled trial52-week treatment period; 57 weeks for the hierarchical composite follow-up
The study result

At week 52, mean body-weight change was −9.8% with semaglutide and −3.4% with placebo; KCCQ clinical summary score change was +13.7 and +6.4 points, respectively.

The estimated between-group difference was −6.4 percentage points for weight and +7.3 points for KCCQ clinical summary score. Six-minute walk distance improved 14.3 meters more with semaglutide. Serious adverse events occurred in 17.7% of semaglutide participants and 28.8% of placebo participants; adverse-event discontinuation occurred in 10.6% and 8.2%, respectively.

Compare programs

Turn the study result into a better program comparison

If this result prompts you to explore GLP-1 care, use it to ask better questions rather than to select a program. Compare providers on available plans, clinician access, medication status, follow-up, public price terms, and enrollment conditions. These reviewed brands have category-matched GLP-1 offers; none participated in or is endorsed by this study.

01
WellMedr logo
WellMedr

From $49 – $129/mo · Editorial score 4.7/5

Featured value terms: semaglutide $49/mo or tirzepatide $89/mo with 12-month prepayment; $99/$129 month to month.

Semaglutide at WellMedr
02
Strut Health logo
Strut Health

From $149 – $399/mo · Editorial score 4.6/5

Semaglutide at Strut Health
03
Trimi logo
Trimi

From $99 – $125/mo · Editorial score 4.8/5

Tirzepatide at Trimi
04
Telos Rx logo
Telos Rx

From $49 – $399/mo · Editorial score 3.9/5

Tirzepatide at Telos Rx
05
HealthRx logo
HealthRx

From $99 – $209/mo · Editorial score 4.1/5

Semaglutide at HealthRx
06
Cielo Health logo
Cielo Health

From $115 – $299/mo · Editorial score 4.4/5

Tirzepatide at Cielo Health

We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology

Study details

Population
616 adults with obesity-related HFpEF, a left-ventricular ejection fraction of at least 45%, and type 2 diabetes
Follow-up
52-week treatment period; 57 weeks for the hierarchical composite follow-up
Treatment comparison
Once-weekly subcutaneous semaglutide escalated to 2.4 mg compared with placebo, added to background diabetes treatment
Study design
Multicountry, double-blind, randomized, placebo-controlled trial
Care and plan considerations

A study result is not a personal treatment plan

The study does not determine whether semaglutide is appropriate for an individual with heart failure or type 2 diabetes. It did not compare online providers, insurance coverage, pharmacies, affordability, or diabetes-care plans. People with heart failure or diabetes should review treatment decisions with their own licensed clinician and care team.

Compare semaglutide and tirzepatide programs

What this result does not show

  • The trial was not designed or powered to establish effects on heart-failure hospitalizations or urgent heart-failure visits; its event count was small.
  • The 52-week follow-up does not establish longer-term durability of the symptom, function, weight, or safety results.
  • The population had obesity-related HFpEF and type 2 diabetes with specific entry criteria, so results do not directly generalize to people without those conditions.
  • The study does not compare telehealth providers, affordability, insurance coverage, pharmacy access, or individual treatment outcomes.
  • The study was funded by Novo Nordisk; the peer-reviewed paper and disclosure materials are linked at the end of this article.
Not sure which provider fits you? Take the 30-second quiz
Answer 4 quick questions to get a personalized provider match
Continue reading

Explore other peer-reviewed results in Evidence Watch before comparing programs or discussing options with a clinician.

All study updates
Study & references

Primary peer-reviewed source

Kosiborod et al., NEJM 2024 · STEP-HFpEF DM

Read the full paper, methodology, conflict-of-interest disclosures, and supplementary materials before drawing conclusions beyond this plain-English summary.

Read the study at New England Journal of Medicine